The Cardio-Oncology Program, a joint collaboration of Brigham and Women's Hospital and Dana-Farber Cancer Institute, is one of a select few of its kind in the country. Led by Anju Nohria, MD, a cardiologist with special training in epidemiology and heart failure, and Javid Moslehi, MD, a cardiologist with additional training is molecular oncology, the Program provides care for cancer patients with a history of cardiovascular disease or those who develop cardiac complications. The program includes both clinical and research components. MORE>>
This innovative program is one of the few in the United States dedicated to addressing the cardiovascular side effects of cancer therapy and maximixing cardiovascular outcomes for cancer survivors.
The specific goals of this Program are as follows:
Provide care for patients with a cardiovascular history who now have to undergo cancer treatment, both medical and surgical procedures;
Provide care for patients who present with heart failure following traditional treatments associated with cardiac dysfunction including anthracyclines, radiation, and newer agents such as herceptin;
Study the potential cardiovascular complications of novel molecular targeted therapies - including arrhythmias, cardiomyopathy, cardiac ischemia, and hypertension - and establish treatment strategies for these complications
Working together as a team in the care of the cancer patient, the goal of the Program is to minimize cardiotoxicity during cancer treatment and cardiovascular risks during cancer survival. MORE>>
Javid J. Moslehi, MD - Co-Director
Anju Nohria, MD - Co-Director
To make an appointment or for additional information about the Cardio-Oncology Program, please contact the Watkins Cardiovascular Clinic at Brigham and Women's Hospital at (857) 307-4000 or Dana-Farber Cancer Institute at (617) 632-4523.
This page was last modified on 9/18/2015